TOP HEADLINES

Featured Story

Mylan launches first generic transdermal contraceptive patch

Mylan Pharmaceutical's Xulane is the first generic contraceptive transdermal patch to hit the market, marking another milestone for the delivery technology.

X-ray-activated nanoparticles release cancer-killing light deeper into tissue

Researchers at the University of Texas at Arlington found that nanoparticles they were studying for radiation detection in the security arena could produce a toxic byproduct able to damage cancer cells.

Stanford team finds that nanotubes catch a ride with immune cells to reach tumors

One way of bypassing the immune system to deliver drugs to a tumor site is to use the immune system itself as a delivery mechanism. And now researchers have unexpectedly found that nanoparticle-encased drugs injected into mice entered immune cells called monocytes, which then carry the treatment to the correct site.

ProNAi, with delivery tech licensed from Marina, snags $59.5M for cancer trials

Detroit-based ProNAi picked up a $59.5 million venture capital round to support its mid-stage DNAi cancer therapy that uses liposomal delivery technology developed by Marina Biotech.

Study: Inhalable encapsulated antibiotic from Aradigm kills 99% of infections

A team of scientists from Oregon State University and Aradigm, a small pulmonary device company out of California, touted successful in vitro results for its inhaled, encapsulated ciproflaxacin treatment for infections associated with the lungs.

MORE NEWS

From Our Sister Sites

FierceBiotech

A hybrid international biotech upstart with deep U.S. academic roots, a company base in Basel and a plan to grow its research operations in London has landed a $25 million A round to launch another effort at gene editing using CRISPR/Cas9 technology--one of the hottest emerging fields in drug development.

FierceMedicalDevices

Lombard Medical revived plans to go public with a revised stateside IPO. The news comes less than two weeks after the company decided to postpone its public offering, citing poor market conditions.